mr DANIEL KRACOV — Lobbyist Profile | Poliscope

mr DANIEL KRACOV

Reported covered position: N/A

Filings

Clients

Firms

Years active

2005–2019

Associated filing income

$3,440,000

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
GENENTECH INC	20	2005–2019
LUNDBECK, INC.	20	2014–2019
ASTELLAS PHARMA US, INC.	12	2007–2011
MEDICIS PHARMACEUTICAL CORPORATION	6	2007–2008
PAIN THERAPEUTICS, INC.	5	2005–2008
PFIZER, INC.	5	2006–2008

Firm	Filings	Years
ARNOLD & PORTER KAYE SCHOLER LLP	82	2005–2019

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

Disclosing Foreign Influence Act

Cited source text

Issues related to the scope of FARA, including H.R. 4170.

Ellie's Law

Cited source text

Issues related to PDUFA and the FDA Reauthorization Act of 2017 (H.R. 2430, S. 934); Ellie's Law (H.R. 1648)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

2019 · fourth_quarter · 4T

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to health care legislation.

2019 · fourth_quarter · Q4

Firm income: $10,000Client expense: —Open original LDA filing ↗